CD19-Targeted CAR-T Cell Therapy: Clinical Overview & Approved Products
An independent clinical reference for CD19-directed CAR-T therapies — approved products, indicated malignancies, resistance mechanisms, and the evidence base.
What is CD19?
CD19 (Cluster of Differentiation 19) is a transmembrane protein expressed almost exclusively on the surface of B-cells, from early developmental stages through mature B-cell differentiation.
It serves as an ideal target for CAR-T therapy because it is highly and uniformly expressed on the vast majority of B-cell malignancies, while its absence on hematopoietic stem cells allows for eventual healthy B-cell recovery post-treatment.
For a detailed explanation of how CAR-T cells are engineered to target specific antigens, please refer to our CAR-T Cell Therapy Hub →
Indicated B-Cell Malignancies
CD19-directed CAR-T therapies are currently established as standard-of-care or highly utilized in specific lines of therapy for the following B-cell malignancies:
- B-cell Acute Lymphoblastic Leukemia (B-ALL) Disease page coming soon
- Diffuse Large B-Cell Lymphoma (DLBCL) Disease page coming soon
- Follicular Lymphoma (FL) Disease page coming soon
- Mantle Cell Lymphoma (MCL) Disease page coming soon
- Chronic Lymphocytic Leukemia (CLL) Disease page coming soon
Specific lines of therapy, age restrictions, and approved indications vary by regulatory body and product. Refer to individual product labels for complete prescribing information.
Approved CD19-Targeted Products
The following products have received regulatory approval (FDA, EMA, or NMPA) for specific relapsed or refractory (r/r) indications. Indications listed are based on FDA and NMPA labels.
| Product Name | Manufacturer | Primary Indication(s) | Approval Year | Region |
|---|---|---|---|---|
| Kymriah tisagenlecleucel | Novartis | r/r B-ALL (pediatric/young adult), r/r DLBCL, r/r FL | 2017 | US / EU |
| Yescarta axicabtagene ciloleucel | Gilead / Kite | r/r LBCL (including DLBCL), r/r FL | 2017 (FL: 2021) | US / EU |
| Tecartus brexucabtagene autoleucel | Gilead / Kite | r/r MCL, r/r B-ALL | 2020 | US / EU |
| Breyanzi lisocabtagene maraleucel | Bristol Myers Squibb | r/r LBCL, r/r FL, r/r MCL, r/r CLL/SLL, r/r MZL | 2021 | US / EU |
| Carteyva / Relma-cel relmacabtagene autoleucel | JW Therapeutics / IASO Bio | r/r Large B-Cell Lymphoma | 2021 | China (NMPA) |
Note: Specific indications, age restrictions, and lines of therapy vary by regional regulatory bodies. Detailed pharmacological profiles for each product will be available on their respective pages. Product pages coming soon
Next-Generation Development: Overcoming Resistance
A known mechanism of resistance to single-target CD19 CAR-T therapy is antigen modulation. To address this, next-generation constructs are actively in clinical development.
CD19/CD22 Dual-Target CAR-T — These therapies are specifically designed to prevent or treat relapse in patients who have experienced CD19-negative relapse following initial CD19-directed therapy.
Level of Evidence
CD19 is the most mature and extensively validated target in the entire CAR-T landscape. With over 8 years of post-marketing clinical data and long-term follow-up studies, it possesses the highest level of clinical evidence among cellular therapies.
This extensive maturity distinctly separates CD19 from emerging solid tumor or novel hematologic targets (e.g., Claudin18.2, GPC3), which remain largely in investigational or early-access phases.
Clinical Limitations & Resistance Mechanisms
Despite high efficacy rates, CD19 CAR-T therapy faces specific, target-related biological limitations:
- Antigen Loss / Escape Downregulation or complete loss of CD19 expression on the tumor cell surface is a primary mechanism of acquired resistance.
- CD19-Negative Relapse Patients may relapse with a CD19-negative clone, rendering subsequent CD19-directed therapies ineffective and often necessitating alternative targets (e.g., CD22) or allogeneic stem cell transplantation.
Clinical Relevance: Antigen loss is a recognized mechanism of relapse. Ongoing research focuses on dual-targeting strategies and next-generation constructs to address this limitation.